Dr. Mutti on Predicting Response to Immunotherapy for Mesothelioma

Luciano Mutti, MD
Published: Thursday, Dec 15, 2016



Luciano Mutti, MD, professor in Cancer Research, University of Salford Manchester, discusses predicting clinical response to immunotherapy agents for patients with mesothelioma.

Determining which patients will be likely to respond to immunotherapeutic agents is difficult, Mutti explains. PD-1/PD-L1 expression is suggested to be a valid biomarker of response, though it is imperfect. Therefore, more well-funded research needs to be conducted to further biomarker development.

Before starting a new treatment for patients with mesothelioma—and across all tumors, he adds—it is imperative that physicians determine the biology of the disease in order to truly administer optimal therapies and test for possible biomarkers and/or alterations.
 


Luciano Mutti, MD, professor in Cancer Research, University of Salford Manchester, discusses predicting clinical response to immunotherapy agents for patients with mesothelioma.

Determining which patients will be likely to respond to immunotherapeutic agents is difficult, Mutti explains. PD-1/PD-L1 expression is suggested to be a valid biomarker of response, though it is imperfect. Therefore, more well-funded research needs to be conducted to further biomarker development.

Before starting a new treatment for patients with mesothelioma—and across all tumors, he adds—it is imperative that physicians determine the biology of the disease in order to truly administer optimal therapies and test for possible biomarkers and/or alterations.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x